-
To evaluate the effectiveness of mammography as a screening test, the authors used the Surveillance, Epidemiology, and End Results (SEER) database to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older in the United States.
-
-
Data were accessed from the nurses health study, which enrolled 121,700 U.S. female registered nurses who were 30-55 years old at the outset in 1976. Every 2 years, participants provided information about their lifestyle, medical history, and illnesses via mailed questionnaires.
-
In this issue: Zolpidem and risk of falls; AVR and anticoagulation; statins in cancer patients; and FDA actions.
-
The authors performed a nested case-control study using data from the Rochester Epidemiology Project which conducts population-based studies of the residents of Olmsted County, Minnesota.
-
The incidence of obesity continues to rise. According to the World Health Organization, 1.5 billion people are overweight, with 300 million obese.1 About two-thirds of the U.S. population is overweight, with one-third being obese.2
-
Alpha-tocopherol is the primary form of vitamin E used in dietary supplements. The results from this study suggest that supplementation with alpha-tocopherol by postmenopausal women may reduce serum gamma-tocopherol levels and negatively impact bone formation.
-
A meta-analysis of 20 human randomized, controlled clinical trials of at least 1 year in duration found that there was no relationship between diet or supplement-derived omega-3 supplementation and cardiovascular disease outcomes.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
Apropos of the recent emphasis on discouraging elective deliveries prior to 39 weeks, a group from Cincinnati embarked on a study to determine whether steroids had any neonatal benefit in patients delivering between 34 and 39 weeks who had immature amniotic fluid lung profiles.